RxDoctor Payments Data

Pedro Figueiredo Ferreira

Nurse Practitioner · Fayetteville, NCNPI 1891401337

Payments from drug & device makers

What this record shows

This record is dominated by other: $30,443 of the $33,215 with a category attached, or 91.7%. Angiodynamics, Inc. accounts for 91.7% of it on its own, with 22 other manufacturers making up the rest. Among nurse practitioner clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$33,215in general payments, 2019–2025

Across 108 payments — averaging $307.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$30K
  • AstraZeneca$322
  • Scpharmaceuticals Inc.$285
  • Boehringer Ingelheim$279
  • Merck$229
  • Amgen$197
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$2,7728%
  • Other$30,44392%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,215 in reported general payments places this provider in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$13,638
Medicare patients
119
Services billed
190

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban137$136,607
XareltoRivaroxaban59$56,261
EntrestoSacubitril/Valsartan27$42,516
JardianceEmpagliflozin27$24,302
Repatha SureclickEvolocumab12$12,886
FarxigaDapagliflozin Propanediol11$10,034
Metoprolol Succinate281$3,190
Diltiazem 24hr Er (Cd)Diltiazem Hcl33$943
Ranolazine ErRanolazine18$912
Potassium Chloride43$840
Rosuvastatin Calcium75$783
Losartan Potassium108$771
Albuterol Sulfate HfaAlbuterol Sulfate38$724
Atorvastatin Calcium81$673
Hydralazine Hcl64$672

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$160$136,607137 claims
Johnson & JohnsonXarelto$159$56,26159 claims
NovartisEntresto$26$42,51627 claims
Boehringer IngelheimJardiance$279$24,30227 claims
AstraZenecaFarxiga$322$10,03411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Fayetteville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →